The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Capital infusion to accelerate Earendil’s R&D platform
Subscribe To Our Newsletter & Stay Updated
